vs

Side-by-side financial comparison of ASGN Inc (ASGN) and Dexcom (DXCM). Click either name above to swap in a different company.

Dexcom is the larger business by last-quarter revenue ($1.3B vs $970.0M, roughly 1.3× ASGN Inc). Dexcom runs the higher net margin — 21.2% vs 0.6%, a 20.7% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs -3.0%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs -3.2%).

ASGN Inc is a leading U.S.-headquartered professional services and workforce solutions provider. It specializes in supplying skilled talent and consulting services across high-growth segments including information technology, creative, digital, life sciences, and engineering, primarily serving enterprise clients across North America.

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

ASGN vs DXCM — Head-to-Head

Bigger by revenue
DXCM
DXCM
1.3× larger
DXCM
$1.3B
$970.0M
ASGN
Growing faster (revenue YoY)
DXCM
DXCM
+24.6% gap
DXCM
21.6%
-3.0%
ASGN
Higher net margin
DXCM
DXCM
20.7% more per $
DXCM
21.2%
0.6%
ASGN
Faster 2-yr revenue CAGR
DXCM
DXCM
Annualised
DXCM
12.0%
-3.2%
ASGN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ASGN
ASGN
DXCM
DXCM
Revenue
$970.0M
$1.3B
Net Profit
$5.5M
$267.3M
Gross Margin
27.5%
62.9%
Operating Margin
2.9%
25.6%
Net Margin
0.6%
21.2%
Revenue YoY
-3.0%
21.6%
Net Profit YoY
-73.7%
153.6%
EPS (diluted)
$0.13
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASGN
ASGN
DXCM
DXCM
Q1 26
$970.0M
$1.3B
Q4 25
$980.1M
$1.3B
Q3 25
$1.0B
$1.2B
Q2 25
$1.0B
$1.2B
Q1 25
$968.3M
$1.0B
Q4 24
$985.0M
$1.1B
Q3 24
$1.0B
$994.2M
Q2 24
$1.0B
$1.0B
Net Profit
ASGN
ASGN
DXCM
DXCM
Q1 26
$5.5M
$267.3M
Q4 25
$25.2M
$267.3M
Q3 25
$38.1M
$283.8M
Q2 25
$29.3M
$179.8M
Q1 25
$20.9M
$105.4M
Q4 24
$42.4M
$151.7M
Q3 24
$47.5M
$134.6M
Q2 24
$47.2M
$143.5M
Gross Margin
ASGN
ASGN
DXCM
DXCM
Q1 26
27.5%
62.9%
Q4 25
28.9%
62.9%
Q3 25
29.4%
60.5%
Q2 25
28.7%
59.5%
Q1 25
28.4%
56.9%
Q4 24
29.0%
58.9%
Q3 24
29.1%
59.7%
Q2 24
29.1%
62.4%
Operating Margin
ASGN
ASGN
DXCM
DXCM
Q1 26
2.9%
25.6%
Q4 25
5.7%
25.6%
Q3 25
6.7%
20.1%
Q2 25
5.8%
18.4%
Q1 25
4.8%
12.9%
Q4 24
7.5%
17.0%
Q3 24
7.7%
15.3%
Q2 24
7.8%
15.7%
Net Margin
ASGN
ASGN
DXCM
DXCM
Q1 26
0.6%
21.2%
Q4 25
2.6%
21.2%
Q3 25
3.8%
23.5%
Q2 25
2.9%
15.5%
Q1 25
2.2%
10.2%
Q4 24
4.3%
13.6%
Q3 24
4.6%
13.5%
Q2 24
4.6%
14.3%
EPS (diluted)
ASGN
ASGN
DXCM
DXCM
Q1 26
$0.13
$0.67
Q4 25
$0.58
$0.67
Q3 25
$0.87
$0.70
Q2 25
$0.67
$0.45
Q1 25
$0.48
$0.27
Q4 24
$0.94
$0.37
Q3 24
$1.06
$0.34
Q2 24
$1.02
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASGN
ASGN
DXCM
DXCM
Cash + ST InvestmentsLiquidity on hand
$143.6M
$917.7M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$1.8B
$2.7B
Total Assets
$4.0B
$6.3B
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASGN
ASGN
DXCM
DXCM
Q1 26
$143.6M
$917.7M
Q4 25
$161.2M
$917.7M
Q3 25
$1.8B
Q2 25
$1.2B
Q1 25
$904.9M
Q4 24
$205.2M
$606.1M
Q3 24
$621.2M
Q2 24
$939.2M
Total Debt
ASGN
ASGN
DXCM
DXCM
Q1 26
$1.5B
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$1.0B
Stockholders' Equity
ASGN
ASGN
DXCM
DXCM
Q1 26
$1.8B
$2.7B
Q4 25
$1.8B
$2.7B
Q3 25
$1.8B
$2.7B
Q2 25
$1.8B
$2.6B
Q1 25
$1.8B
$2.3B
Q4 24
$1.8B
$2.1B
Q3 24
$1.8B
$2.0B
Q2 24
$1.8B
$2.4B
Total Assets
ASGN
ASGN
DXCM
DXCM
Q1 26
$4.0B
$6.3B
Q4 25
$3.7B
$6.3B
Q3 25
$3.7B
$7.5B
Q2 25
$3.7B
$7.3B
Q1 25
$3.7B
$6.8B
Q4 24
$3.4B
$6.5B
Q3 24
$3.4B
$6.4B
Q2 24
$3.5B
$6.8B
Debt / Equity
ASGN
ASGN
DXCM
DXCM
Q1 26
0.82×
Q4 25
0.65×
Q3 25
0.64×
Q2 25
0.66×
Q1 25
0.72×
Q4 24
0.58×
Q3 24
0.58×
Q2 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASGN
ASGN
DXCM
DXCM
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$9.1M
FCF MarginFCF / Revenue
0.9%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$290.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASGN
ASGN
DXCM
DXCM
Q1 26
Q4 25
$102.3M
$294.0M
Q3 25
$83.9M
$659.9M
Q2 25
$124.9M
$303.0M
Q1 25
$16.8M
$183.8M
Q4 24
$100.2M
$301.4M
Q3 24
$135.8M
$199.5M
Q2 24
$90.7M
$279.4M
Free Cash Flow
ASGN
ASGN
DXCM
DXCM
Q1 26
$9.1M
Q4 25
$93.7M
$192.1M
Q3 25
$72.0M
$579.4M
Q2 25
$115.8M
$208.9M
Q1 25
$6.6M
$96.8M
Q4 24
$88.9M
$176.8M
Q3 24
$127.9M
$88.3M
Q2 24
$85.4M
$213.3M
FCF Margin
ASGN
ASGN
DXCM
DXCM
Q1 26
0.9%
Q4 25
9.6%
15.3%
Q3 25
7.1%
47.9%
Q2 25
11.3%
18.1%
Q1 25
0.7%
9.3%
Q4 24
9.0%
15.9%
Q3 24
12.4%
8.9%
Q2 24
8.3%
21.2%
Capex Intensity
ASGN
ASGN
DXCM
DXCM
Q1 26
1.0%
Q4 25
0.9%
8.1%
Q3 25
1.2%
6.7%
Q2 25
0.9%
8.1%
Q1 25
1.1%
8.4%
Q4 24
1.1%
11.2%
Q3 24
0.8%
11.2%
Q2 24
0.5%
6.6%
Cash Conversion
ASGN
ASGN
DXCM
DXCM
Q1 26
Q4 25
4.06×
1.10×
Q3 25
2.20×
2.33×
Q2 25
4.26×
1.69×
Q1 25
0.80×
1.74×
Q4 24
2.36×
1.99×
Q3 24
2.86×
1.48×
Q2 24
1.92×
1.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons